Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

KEMRI-PHRD UG1 CASCADE NETWORK UNIT: CERVICAL CANCER PREVENTION FOR WOMEN LIVING WITH HIV RESEARCH

Award Number: UG1CA285132
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/19/2023
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

KEMRI-PHRD UG1 CASCADE NETWORK UNIT: CERVICAL CANCER PREVENTION FOR WOMEN LIVING WITH HIV RESEARCH - KEMRI-PHRD CLINICAL TRIAL SITE FOR CASCADE NETWORK ‘CERVICAL CANCER PREVENTION FOR WOMEN LIVING WITH HIV Project Summary/Abstract: Cervical cancer is the leading cause of cancer-related deaths in women in eastern and southern Africa, the regions with the highest burden of HIV infection globally. (1) In East Africa, 2020 estimates reported that a quarter of new cervical cancer cases could be attributed to HIV infection. (2) Cervical cancer morbidity and mortality reflects global inequity with the most vulnerable populations carrying the greatest disease burden. The KEMRI-CCR-PHRD research clinic in partnership with LVCT Health Dhibiti HIV/TB PEPFAR/CDC program (supporting 31,800 PLHIV in central region of Kenya) have organized a consortium of HIV and cervical cancer clinical, research and program experts and through this application propose to join the UG1 as a Network clinical trial site and implement HIV/cervical cancer prevention studies. We propose to implement the UG1 Network studies at three selected HIV care clinics based in rural urban public hospitals in Kiambu county (Thika level 5, Ruiru level 4, Igegania level 4 hospitals). The three selected hospitals are part of ten reproductive health (RH) clinics implementing the ‘TIBA’ study (5R01CA258590-02 Mugo), an implementation science study evaluating the implementation of Screen and Treat (SAT) + Single Visit Approach (SVA) with Thermal Ablation (TA). We have capacity and resources to participate in all four proposed focal UG1 research areas; increase screening uptake, improve management of screen positives, facilitate precancer treatment access and optimize precancer treatments for cervical cancer prevention for WLWH. Through partnership with LVCT Health Dhibiti HIV/TB CDC/PEPFAR funded care program and leveraging on- going implementation science studies conducted in the selected public health facilities, we propose in Aim 1, to provide infrastructure to recruit, enroll and retain WLWH to the UG1 network studies. The three selected facilities have an estimate of 4,000 WLWH enrolled in the HIV/TB care clinics, with the option to expand to 10,000 by incorporating the ten TIBA study clinics. In Aim 2, we propose to interface with the UG1 Research Bases and U24 Network Coordinating Center during concept and protocol development to provide insights and input on issues pertaining to clinical significance, study feasibility, implementation and contribute towards raising up relevant priority research questions. KEMRI-CCR-PHRD co-PIs have participated in multiple multisite clinical trials and have been protocol chairs on network studies. In Aim 3, we propose to provide on-site operational leadership for the successful conduct of the network clinical trials. The KEMRI-CCR-PHRD research unit has 16 years’ experience conducting clinical research and has well tested standardized systems and materials for implementation of research in accordance with international regulatory requirements.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $216,000 )
2025	2025	KENYA MEDICAL RESEARCH INSTITUTE	OFF MBAGATHI ROAD	NAIROBI CITY				KEN	Cancer Control	000	3	9/4/2025	NON-COMPETING CONTINUATION	$172,013
2025	2025	KENYA MEDICAL RESEARCH INSTITUTE	OFF MBAGATHI ROAD	NAIROBI CITY				KEN	Cancer Control	001	3	9/11/2025	SUPPLEMENT FOR EXPANSION	$43,987
														Subtotal = $216,000

Issue Date FY: 2024 ( Subtotal = $333,259 )
2024	2024	KENYA MEDICAL RESEARCH INSTITUTE	OFF MBAGATHI ROAD	NAIROBI CITY				KEN	Cancer Control	001	2	6/14/2024	NON-COMPETING CONTINUATION	$216,000
2024	2024	KENYA MEDICAL RESEARCH INSTITUTE	OFF MBAGATHI ROAD	NAIROBI CITY				KEN	Cancer Control	002	2	9/11/2024	NON-COMPETING CONTINUATION	$117,259
2024	2023	KENYA MEDICAL RESEARCH INSTITUTE	OFF MBAGATHI ROAD	NAIROBI CITY				KEN	Cancer Control	000	1	10/16/2023	NEW	$0
														Subtotal = $333,259

Issue Date FY: 2023 ( Subtotal = $216,000 )
2023	2023	KENYA MEDICAL RESEARCH INSTITUTE	OFF MBAGATHI ROAD	NAIROBI CITY				KEN	Cancer Control	000	1	9/19/2023	NEW	$216,000
														Subtotal = $216,000

Grand Total All Awards = $765,259

Top

All Categories

About

Search

Reports

Data Submission

Award Information

KEMRI-PHRD UG1 CASCADE NETWORK UNIT: CERVICAL CANCER PREVENTION FOR WOMEN LIVING WITH HIV RESEARCH

Award Number: UG1CA285132

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/19/2023

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer